

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

Brilliant Violet 785(TM) anti-human CD8

RRID:AB_2566202

Type: Antibody

Proper Citation

BioLegend Cat# 344740, RRID:AB_2566202

Antibody Information

URL: http://antibodyregistry.org/AB_2566202

Proper Citation: BioLegend Cat# 344740, RRID:AB_2566202

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_2566202

Vendor: BioLegend

Catalog Number: 344740

Alternative Catalog Numbers: 344739

Record Creation Time: 20250819T224441+0000

Record Last Update: 20250820T031002+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-human CD8.

No alerts have been found for Brilliant Violet 785(TM) anti-human CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Stockmann AP, et al. (2025) DF6215, an α -optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity. *Cell reports. Medicine*, 102518.

Laheurte C, et al. (2025) UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity. *Cell reports. Medicine*, 6(7), 102196.

Kirk AM, et al. (2024) DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma. *Cell reports. Medicine*, 5(3), 101469.

Motte J, et al. (2024) Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells. *Neuron*, 112(11), 1757.

Ciacchi L, et al. (2023) CD4+ T cell-mediated recognition of a conserved cholesterol-dependent cytolysin epitope generates broad antibacterial immunity. *Immunity*, 56(5), 1082.

Parry EM, et al. (2023) ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. *Cancer cell*, 41(10), 1803.

Alam A, et al. (2022) Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. *Cancer cell*, 40(2), 153.

Zheng C, et al. (2022) Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers. *Cancer cell*, 40(4), 410.

Shuwa HA, et al. (2021) Alterations in T and B cell function persist in convalescent COVID-19 patients. *Med (New York, N.Y.)*, 2(6), 720.

Mogilenko DA, et al. (2021) Comprehensive Profiling of an Aging Immune System Reveals Clonal GZMK+ CD8+ T Cells as Conserved Hallmark of Inflammaging. *Immunity*, 54(1), 99.

Krämer B, et al. (2021) Early IFN- γ signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. *Immunity*, 54(11), 2650.

Schulte-Schrepping J, et al. (2020) Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. *Cell*, 182(6), 1419.

De Domenico E, et al. (2020) Optimized workflow for single-cell transcriptomics on infectious diseases including COVID-19. *STAR protocols*, 1(3), 100233.